




CERTIFIED REFERENCE MATERIAL CERTIFICATE OF ANALYSIS

NMIA D991: α -Methyltryptamine

Report ID: D991.2021.02 (Bottled 150929)

Chemical Formula: $C_{11}H_{14}N_2$

Molecular Weight: 174.2 g/mol



Certified value

Batch No.	CAS No.	Purity (mass fraction)
12-D-24	299-26-3	99.4 ± 1.0%

The uncertainty has been calculated according to ISO Guide 35 and is stated at the 95% confidence limit ($k = 2$).

IUPAC name: 1-(1H-Indol-3-yl)-2-propanamine

Expiration of certification: The property values are valid till 09 June 2026, i.e. five years from the date of re-certification provided the **unopened** material is handled and stored in accordance with the recommendations below. The material as issued in the unopened container and stored as recommended below should be suitable for use beyond this date, subject to confirmation of batch stability from the issuing body. The expiry date/shelf life does not apply to sample bottles that have been opened. In such cases it is recommended that the end-user conduct their own in-house stability trials.

Description: Off-white powder sourced from an external supplier, certified for identity and purity by NMIA. Packaged in amber glass bottles with a septum and crimped aluminium cap or screw top cap.

Intended use: This certified reference material is suitable for use as a primary calibrator.

Instructions for use: Equilibrate the bottled material to room temperature before opening.

Recommended storage: When not in use this material should be stored at or below 25 °C in a closed container in a dry, dark area.

Metrological traceability: The certified purity value is traceable to the SI unit for mass (kg) through Australian national standards via balance calibration. In the mass balance approach all impurities are quantified as a mass fraction and subtracted from 100%. Quantitative NMR provides an independent direct measure of the mass fraction of the analyte of interest, calibrated with an internal standard certified for purity (mass fraction).

Stability: This material has demonstrated stability over a minimum period of three years. The measurement uncertainty at the 95% confidence interval includes a stability component which has been estimated from annual stability trials. The long-term stability of the compound in solution has not been examined.

Homogeneity assessment: The homogeneity of the material was assessed using purity assay by GC-FID on ten randomly selected 1-2 mg sub samples of the material. The material was judged to be sufficiently homogeneous at this level of sampling as the variation in analysis results between samples was not significantly different at a 95% confidence level from that observed on repeat analysis of the same sample.

Safety: Treat as a hazardous substance. Use appropriate work practices when handling to avoid skin or eye contact, ingestion or inhalation of dust. Refer to the provided safety data sheet.

S. R. Davies

Dr Stephen R. Davies,
Team Leader,
Chemical Reference Materials, NMI.
21 September 2022

This report supersedes any issued prior to 21 September 2022.

NATA Accreditation No. 198 / Corporate Site No. 14214.

Legal notice: Terms and Conditions associated with the provision of this reference material can be found on the NMIA website.

Characterisation Report:

The purity value was obtained from a combination of traditional analytical techniques and quantitative nuclear magnetic resonance (qNMR). The techniques used in the mass balance approach include GC-FID thermogravimetric analysis, Karl Fischer analysis and ¹H NMR spectroscopy. The purity value is calculated as per Equation 1.

$$\text{Purity} = (100\% - I_{\text{ORG}}) \times (100\% - I_{\text{VOL}} - I_{\text{NVR}}) \quad \text{Equation 1}$$

I_{ORG} = Organic impurities of related structure, I_{VOL} = volatile impurities, I_{NVR} = non-volatile residue

The purity estimate by qNMR was obtained using a combination of the one proton doublet of doublets of doublets at 2.67 and 2.91 ppm and the one proton multiplet at 3.32 ppm against a certified internal standard of hexamine.

Supporting evidence is provided by headspace GC-MS analysis of occluded solvents and elemental microanalysis.

GC-FID:	Instrument:	Agilent 7890
	Column:	HP-1, 30 m × 0.32 mm I.D. × 0.25 μm
	Program:	120 °C (1 min), 8 °C/min to 200 °C, 30 °C/min to 300 °C (3 min)
	Injector:	250 °C
	Detector Temp:	320 °C
	Carrier:	Helium
	Split ratio:	20/1
	Relative mass fraction of the main component:	
	Initial analysis:	Mean = 99.9%, s = 0.01% (10 sub samples in duplicate, October 2012)
	Re-analysis:	Mean = 99.9%, s = 0.01% (5 sub samples in duplicate, September 2013)
	Re-analysis:	Mean = 99.8%, s = 0.03% (5 sub samples in duplicate, August 2014)
	Re-analysis:	Mean = 99.9%, s = 0.01% (5 sub samples in duplicate, August 2015)
	Re-analysis:	Mean = 99.8%, s = 0.03% (5 sub samples in duplicate, July 2018)
	Re-analysis:	Mean = 99.8%, s = 0.01% (5 sub samples in duplicate, June 2021)
Thermogravimetric analysis:	Non volatile residue < 0.2% mass fraction (October 2012). The volatile content (e.g. organic solvents and/or water) could not be determined because of the inherent volatility of the material.	
Karl Fischer analysis:	Moisture content 0.1% mass fraction (October 2012) Moisture content < 0.1% mass fraction (September 2013) Moisture content 0.1% mass fraction (August 2014) Moisture content 0.1% mass fraction (August 2015) Moisture content 0.1% mass fraction (June 2018) Moisture content < 0.1% mass fraction (June 2021)	
qNMR:	Instrument:	Bruker Avance-III-400
	Field strength:	400 MHz
	Solvent:	CDCl ₃ (7.26 ppm)
	Internal standard:	Hexamine (99.9% mass fraction) (2012) Dimethyl terephthalate (100 % mass fraction) (2014)
	Initial analysis:	Mean (2.67, 2.91 ppm) = 98.4%, s = 0.4% (3 sub samples, November 2012)
	Re-analysis:	Mean (3.32 ppm) = 98.1 %, s = 0.4% (3 sub samples, November 2012)
	Re-analysis:	Mean (3.32 ppm) = 99.1 %, s = 0.5% (5 sub samples, August 2014)

Spectroscopic and other characterisation data

GC-MS:	Instrument: Agilent 6890/5973 Column: TG-1MS, 30 m x 0.25 mm I.D. x 0.25 μ m Program: 120 $^{\circ}$ C (1 min), 10 $^{\circ}$ C/min to 280 $^{\circ}$ C (2 min) Injector: 250 $^{\circ}$ C Transfer line temp: 280 $^{\circ}$ C Carrier: Helium, 1.0 mL/min Split ratio: 20/1 The retention time of the parent compound is reported along with the major peaks in the mass spectrum/spectra. The latter are reported as mass/charge ratios and (in brackets) as a percentage relative to the base peak. Parent (9.1 min): 174 (M^+ , 3), 131 (100), 103 (9), 77 (13), 51 (3) m/z
HS-GC-MS:	Instrument: Agilent 6890/5973/G1888 Column: DB-624, 30 m x 0.25 mm I.D. x 1.4 μ m Program: 50 $^{\circ}$ C (5 min), 7 $^{\circ}$ C/min to 120 $^{\circ}$ C, 15 $^{\circ}$ C/min to 220 $^{\circ}$ C (8.3 min) Injector: 150 $^{\circ}$ C Transfer line temp: 280 $^{\circ}$ C Carrier: Helium, 1.2 mL/min Split ratio: 50/1 Solvents detected: Benzene
TLC:	Conditions: Kieselgel 60F254. Chloroform/methanol/diethylamine (19/1/1) Single spot observed, R_f = 0.24. Visualisation with UV at 254 nm
IR:	Instrument: Biorad FTS3000MX FT-IR Range: 4000-400 cm^{-1} , KBr powder Peaks: 3357, 3294, 3136, 3100, 3036, 2916, 2864, 2607, 1578, 1452, 1356, 1231, 1106, 1088, 1010, 966, 926, 905, 809, 741 cm^{-1}
1H NMR:	Instrument: Bruker Gyro-300 Field strength: 300 MHz Solvent: $CDCl_3$ (7.26 ppm) Spectral data: δ 1.20 (3H, d, J = 6.3 Hz), 1.36 (2H, bs), 2.67 (1H, ddd, J = 0.5, 8.3, 14.2 Hz), 2.91 (1H, ddd, J = 0.8, 4.9, 14.2 Hz), 3.32 (1H, m), 7.02 (1H, bd, J = 2.2 Hz), 7.13 (1H, ddd, J = 1.2, 7.1, 8.1 Hz), 7.20 (1H, ddd, J = 1.3, 7.1, 8.1 Hz), 7.36 (1H, ddd, J = 0.9, 1.1, 8.1 Hz), 7.63 (1H, dddd, J = 7.9, 1.4, 0.7, 0.7 Hz), 8.51 (1H, bs) ppm Benzene estimated at 0.2% mass fraction was observed in the 1H NMR
13C NMR:	Instrument: Bruker Gyro-300 Field strength: 75 MHz Solvent: $CDCl_3$ (77.0 ppm) Spectral data: δ 23.7, 36.0, 47.3, 111.1, 113.6, 119.0, 119.1, 121.8, 122.4, 127.7, 136.4 ppm
Melting point:	96-98 $^{\circ}$ C
Microanalysis:	Found: C = 76.1%; H = 8.3%; N = 16.2% (October, 2012) Calculated: C = 75.8%; H = 8.1%; N = 16.1% (Calculated for $C_{11}H_{14}N_2$)